Nasdaq4d
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its lead drug, Amvuttra (vutrisiran), for treating the cardiomyopathy of ...
Zacks Investment Research on MSN4d
Alnylam Gets FDA Nod for Expanded Use of Amvuttra in Cardiomyopathy
Alnylam Pharmaceuticals ALNY announced that the FDA had approved its regulatory filing seeking the label expansion of its ...
pharmaphorum1d
Alnylam's Onpattro is first ever FDA-approved RNAi drug
The FDA has approved the first ever RNA interference drug – Alnylam’s Onpattro (patisiran) for the nerve damage caused by the rare disease hereditary transthyretin-mediated amyloidosis (hATTR ...
Medscape1d
New Management Approaches for Gastroparesis
In addition to treating symptoms, prokinetic drugs could potentially improve glycemic control in diabetic gastroparesis by allowing a more predictable absorption of nutrients, matched to the ...